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ABSTRACT
We have previously found that UV-induced DNA dam-
age causes hyperphosphorylation of the carboxy ter-
minal domain (CTD) of RNA polymerase II (RNAPII),
inhibition of transcriptional elongation and changes
in alternative splicing (AS) due to kinetic coupling
between transcription and splicing. In an unbiased
search for protein kinases involved in the AS re-
sponse to DNA damage, we have identified glycogen
synthase kinase 3 (GSK-3) as an unforeseen partic-
ipant. Unlike Cdk9 inhibition, GSK-3 inhibition only
prevents CTD hyperphosphorylation triggered by UV
but not basal phosphorylation. This effect is not due
to differential degradation of the phospho-CTD iso-
forms and can be reproduced, at the AS level, by over-
expression of a kinase-dead GSK-3 dominant neg-
ative mutant. GSK-3 inhibition abrogates both the
reduction in RNAPII elongation and changes in AS
elicited by UV. We show that GSK-3 phosphorylates
the CTD in vitro, but preferentially when the substrate
is previously phosphorylated, consistently with the
requirement of a priming phosphorylation reported
for GSK-3 efficacy. In line with a role for GSK-3 in the
response to DNA damage, GSK-3 inhibition prevents
UV-induced apoptosis. In summary, we uncover a
novel role for a widely studied kinase in key steps
of eukaryotic transcription and pre-mRNA process-
ing.
INTRODUCTION
Gene expression is tightly regulated by external and inter-
nal cues. This includes gene expression activation and in-
hibition, i.e. regulation of transcription both at the initia-
tion and elongation levels, as well as the generation of dif-
ferent mRNA variants. Co-transcriptional RNA process-
ing events are greatly influenced by RNAPII transcription
kinetics. In particular, alternative splicing (AS) decisions
can be modulated by elongation rates, as explained by the
kinetic model of coupling between transcription and AS:
changes in the speed of elongation affect the time of emer-
gence of nascent pre-mRNA, creating different windows of
opportunity for the binding of positive and negative splic-
ing factors to both splicing sites and splicing enhancers and
silencers (1). This phenomenon can explain upregulation
of both alternative exon cassette inclusion or skipping at
low elongation rates, depending on the architecture of the
nascent RNA and the nature of the splicing regulatory ele-
ments (2,3).
Rpb1, the largest subunit of RNAPII, has a distinctive
feature: it has a long repetitive carboxy terminal domain
(CTD) of the consensus heptapeptide YSPTSPS. The CTD
is highly conserved among eukaryotes, with variation in its
length. For instance, in yeast the CTD comprises 26 repeats,
while in humans, 52. The CTD is largely modified by phos-
phorylation along gene transcription. According to a classic
paradigm, CTD phosphorylation at Ser5 (P-Ser5) by Cdk7,
the kinase subunit of TFIIH, is a hallmark of transcription
initiation, while the transition from initiation to productive
elongation is mediated by Ser2 phosphorylation by Cdk9,
a component of the P-TEFb complex. Though instrumen-
tal to depict the transcription cycle, the real situation is
much more complex due to, at least, three reasons. First,
because of its repetitive nature, it is challenging to know
the detailed phosphorylation pattern of the whole CTD.
In this sense, a big effort was done by the Eick lab, who
showed that there is a high variability of phospho- amino
acid combinations within single and adjacent heptads, thus
demonstrating the heterogeneity along the CTD (4). Sec-
ond, as kinases and phosphatases modify the CTD along
the gene body, the phosphorylation state of the CTD varies
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pronouncedly. In fact, intragenic P-Ser5 signal was detected
while transcribing alternative exons (5) and Proudfoot and
Carmo-Fonseca’s labs showed that, in particular, there are
high peaks of P-Ser5 positioned at 5′ splice sites that co-
ordinate splicing with transcription (6). Third, apart from
the canonical Cdk7 and Cdk9 duet, there are other kinases
that modify the CTD. Ser2 phosphorylations downstream
into the gene body are catalyzed by Cdk12 and Cdk13 (7)
and modulate RNA processing events (8). P-Thr4 marks
are placed by Plk3 on RNAPII located towards the 3′ end
of genes (9). The kinase Dyrk1A binds to the promoter
of a subset of genes and promotes transcription by phos-
phorylating the CTD (10) and, in complex with DCAF7,
is tethered to RNAPII and promotes myogenesis (11). The
atypical kinase BRD4 was also shown to phosphorylate the
CTD in vitro (12) and its activity is relevant for AS regu-
lation during thymocyte differentiation (13). Finally, a re-
cent screening of yeast kinases unveiled novel P-Thr4 CTD
kinases, and that hrr25, the yeast homolog of CK1, regu-
lates snoRNA maturation via phosphorylation of RNAPII
at Thr4, thus supporting the concept of gene-class-specific
CTD kinases (14).
UV-induced DNA damage triggers a transcriptional
response that modifies transcription and AS patterns
genome-wide in the context of the kinetic coupling model
(15,16). This response consists of two parallel mecha-
nisms. The in cis response starts with the encounter of a
transcribing RNAPII with a DNA lesion which triggers
transcription-coupled nucleotide excision repair pathway
(TC-NER) (17–19). The in trans response that we study here
is independent from TC-NER and consists of a signaling
that begins with the repair of the UV-induced cyclobutane
pyrimidine dimers (CPDs) by the global genome nucleotide
excision repair pathway (GG-NER) and results in an exten-
sive hyperphosphorylation of the RNAPII CTD, detected
by western blot as an increase in RNAPII O isoform (hy-
perphosphorylated) with respect to RNAPII A (hypophos-
phorylated). In turn, this phosphorylation correlates with
reduced transcription elongation rates that change AS pat-
terns in the context of the kinetic coupling model. ATR,
a paramount DNA damage response kinase, is involved in
this signaling in skin cells, probably indirectly (20). Cdk9,
as part of P-TEFb, is also involved. Evidence of this is that
camptothecin or UV treatment induce the dissociation of
P-TEFb from its inhibitory counterpart HEXIM/7SK and
promote RNAPII CTD hyperphosphorylation (21,22). It
is worth noting, however, that the treatment with Cdk9 in-
hibitors per se induces a complete switch in RNAPII west-
ern blot signal towards RNAPII A. Thus, though necessary
to promote RNAPII hyperphosphorylation, Cdk9 may not
be the only kinase involved.
Given this scenario, we were interested in finding new ki-
nases participating in the transcriptional response to DNA
damage. Therefore, we developed a screening strategy based
on an AS fluorescent reporter that allowed us to test ca. 700
kinase inhibitors to identify those that reduce or abolish the
AS response to UV-induced DNA damage. Glycogen syn-
thase kinase 3 (GSK-3) emerged as the principal common
target, so we centered our attention in understanding its role
in this response. Here we show that GSK-3 inhibition pre-
vents RNAPII hyperphosphorylation and changes in AS
patterns and transcription elongation rates in response to
UV irradiation. The inhibitory drug effect is not due to
differential degradation of the phospho-CTD isoforms and
can be reproduced, at the AS level, by overexpression of a
kinase-dead GSK-3 dominant negative mutant, which sup-
ports an in vivo role for GSK-3 in the in trans pathway.
In vitro experiments show that GSK-3 phosphorylates the
CTD directly but preferentially when the substrate is previ-
ously phosphorylated by another kinase such as Cdk9, con-
sistently with the requirement of a priming phosphorylation
reported for GSK-3 (23). In line with a role for GSK-3 in the
transcriptional response to DNA damage, GSK-3 inhibi-
tion prevents UV-induced apoptosis. In summary, data pre-
sented in this paper position GSK-3 as a novel CTD kinase
responsible for the RNAPII hyperphosphorylation caused
by DNA damage, thus assigning a novel role for this widely-
studied kinase.
MATERIALS AND METHODS
Cell culture and treatments
HeLa and HEK293T cells were cultured as indicated by
ATCC. HeLa Flp-In T-REx cells were gently provided
by Matthias Hentze. HeLa Flp-In T-Rex cells were cul-
tured in the presence of zeocin (Invitrogen) 100 g/ml and
blasticidin (Invivogen) 5 g/ml. HeLa Flp-In T-REx sta-
bly transfected cells were cultured in the presence of hy-
gromycin (Invivogen) 100 g/ml and blasticidin 5 g/ml.
Tet-on promoters were induced by the addition of tetra-
cycline (Sigma) 1 g/ml. Endogenous RNAPII inhibition
was achieved by the addition of -amanitin (Sigma) 10
g/ml. UV irradiation was performed as described previ-
ously (20). GW806290X and GW805758X (GlaxoSmithK-
line) were used at 0.1 and 0.5 M respectively. Commercial
GSK-3 inhibitors CHIR99021 and AR-A 014418 (Sigma)
were used at 10 and 20 M respectively. Cdk7/9 inhibitor
DRB (Sigma) was used at 50 M. Actinomycin D was used
at 10 g/ml. MG132 was used at 10 M.
Transfections and stable cell lines
Transfections were performed using Lipofectamine 2000
(Thermo Scientific) according to the manufacturer’s in-
structions. Flp-In T-REx stable cell lines were obtained by
co-transfection of the gene of interest cloned in the plasmid
pCDNA5/FRT/TO and the plasmid pOG44, according to
the manufacturer’s manual (Invitrogen). WT and K85A
GSK-3 constructs were gently provided by Scott Fried-
man. For experiments where GSK-3 expression plasmids
and AS reporter minigene plasmids were co-transfected, a
ratio 9:1 of former to the latter plasmid was used in the
transfection mix.
RNA extraction, RT-PCR, RT-qPCR and qPCR
RNA was purified using TriPure reagent (Roche Life Sci-
ence). RT reactions were performed with MM-LV RT (In-
vitrogen) following the manufacturer’s instructions using
random decamers as primers. PCR and qPCR conditions
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Western blot
Protein samples were prepared in 2× Laemmli buffer. West-
ern blot procedures and antibodies are detailed in the Sup-
plemental Experimental Procedures.
Epifluorescence microscopy and data analysis
Cells growing in Lab-Tek II chambers (Thermo) were fixed
by incubation with 4% PFA in PBS for 10 min and rinsed
3 times in PBS. Nuclei were stained by addition of DAPI 1
g/ml in PBS. Images were obtained with an Olympus IX81
epifluorescence microscope and processed with the CellPro-
filer software (Broad Institute) to segment nuclei and quan-
tify dsRed and GFP fluorescence signal. Data analysis was
performed with RStudio software.
CPD removal by CPD photolyase
HeLa cells expressing the marsupial CPD photolyase of Po-
torous tridactylus were obtained via the Flp-In T-REx sys-
tem by subcloning the photolyase used previously (20) in
the plasmid pcDNA5/FRT/TO. Photolyase expression was
induced by addition of tetracycline to the culture medium
for 24 h prior to transfection with the fluorescent reporter.
Immediately after irradiation, tetracycline was re-added to
induce the fluorescent reporter and cells were exposed to
white light to activate the photolyase-mediated CPD re-
moval or kept in the dark as a control.
Kinase inhibitors screening and data analysis
The screening with PKIS2 (GlaxoSmithKline) kinase in-
hibitor library was divided in subsets. For each subset, 10
000 HeLa eRGi cells were plated in 96-well plates. Twenty-
four hours later, cells were irradiated (or not) with 5 J/m2 of
UV light, and tetracycline and a different kinase inhibitor
at 0.1 M in each well (or DMSO as a vehicle control) were
added immediately. Twenty-four hours later, cells were har-
vested by trypsinization and GFP and dsRed* fluorescence
signal were acquired in a robot-assisted flow cytometer At-
tune NxT (Thermo). Prior to trypsinization, cells were ob-
served at the microscope to detect any possible toxicity as-
sociated with the inhibitor treatment.
The data obtained with the flow cytometer were ana-
lyzed with RStudio software as follows: (i) mean GFP sig-
nal over mean dsRed signal (GFP signal)/(dsRed signal)
was calculated for each well, both for the non-irradiated
and the irradiated plates; (ii) for each plate, the average
(GFP signal)/(dsRed signal) of the four vehicle control
(DMSO) wells and its associated error were calculated and
noted as DMSOCtrl ± s or DMSOUV ± s; (iii) the ratio of
DMSOUV/DMSOCtrl, defined as QDMSO ± s, represents the
average effect of UV treatment with vehicle; (iv) for each
inhibitor, the ratio (GFP signal)/(dsRed signal) was cal-
culated for non-irradiated and UV irradiated cells, noted
as InhCtrl and InhUV respectively. The ratio InhUV/InhCtrl
was noted as QInh, and corresponds to the effect of UV
treatment when cells are treated with the corresponding in-
hibitor; (v) inhibitors were considered positive hits when
QInh was greater or less than QDMSO ± 2s and the percentage
of change was equal or more than 15%. Positive hits were
repeated in an independent experiment to rule out false-
positive hits.
In vitro kinase assays
GST-CTD constructs were expressed in E. coli and pre-
pared as indicated previously (24). To prepare Cdk9, GSK-
3 and HA-tagged WT and KD GSK-3, HEK293T cells
were lysed at 4◦C for 30 min in IP buffer (20 mM HEPES
pH 7.4, 1% Igepal, 150 mM NaCl, 10 mM KCl, 0.1 mM
EGTA, 0.1 mM EDTA, 1 mM DTT, 1× PhosStop (Roche)
phosphatase inhibitor cocktail and 1× cOmplete (Roche)
protease inhibitor cocktail). Lysates were cleared by cen-
trifugation at 12 000 g for 10 min and the indicated antibody
was added to 1.6 mg of total protein and incubated with ro-
tation at 4◦C for 2 h. Aliquots of 30 l of Dynabeads Pro-
tein G (Thermo) were equilibrated and added to the anti-
body:lysate suspensions and incubated with rotation at 4◦C
for two additional hours. Beads were rinsed twice with 500
l of IP buffer and twice with 500 l of kinase buffer (60
mM HEPES pH 7.4, 10 mM MgCl2, 1 mM MnCl2, 1.2 mM
DTT, 1× PhosStop (Roche) phosphatase inhibitor cocktail
and 1× cOmplete (Roche) protease inhibitor cocktail) and
finally resuspended in 30 l of kinase buffer. Kinase reac-
tions were performed at 30◦C by addition of 10 l of kinase
attached to the beads to 100 ng of GST-CTD in a final vol-
ume of 30 l with ATP at 250 M for Cdk9 reactions or
at 1 mM for GSK-3 reactions. Rabbit normal IgG was used
as a control for GSK-3 reactions. When added, CHIR99021
was used at 10 M. Kinase immunoprecipitations were per-
formed with anti Cdk9 (C-20, Santa Cruz), anti GSK-3
(27C10, Cell Signaling) and anti HA (H6908, Sigma).
Differential cell extract preparation
The differential salt extractability protocol used was de-
scribed previously (21).
Chromatin immunoprecipitation
RNAPII ChIP experiments were performed as in (25) with
Rpb1 NTD (D8L4Y) rabbit antibody (Cell Signaling).
Propidium iodide and FITC-annexin V staining
Apoptosis staining was performed with Annexin V-FITC
Apoptosis detection kit (BD) following the manufacturer’s
instructions and analyzed in a FACS Aria II flow cytometer
(BD).
Cloning, subcloning and reverse fluorescent reporter con-
struction
The original version of the fluorescent alternative splicing
reporter was a gentle gift of Thomas Cooper. The original
reporter was subcloned in the plasmid pcDNA5/FRT/TO
with the enzymes HindIII and ApaI. Mutagenesis of dsRed
(H41T/N42Q/V44A) and the reverse reporter were ob-
tained by traditional site-directed mutagenesis. Primers
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Cloning of the TMEM188-E2 AS reporter minigene
TMEM188-E2 minigene was obtained by cloning a DNA
fragment containing the alternative exon E2, its flanking in-
trons, and part of the upstream and downstream exons into
the BstEII sites of the TBX3-E2a minigene vector (20). The
primers used for cloning are detailed in the Supplemental
Experimental Procedures.
CRISPR/Cas9 mediated knock-out
GSK-3 and GSK-3 knock-out cells were obtained ac-





An improved fluorescent reporter for alternative splicing
In order to identify new protein kinases involved in the
transcriptional and AS response to UV-induced DNA dam-
age, we decided to modify an AS fluorescent reporter de-
veloped by the Cooper lab (27). This reporter includes the
28-bp alternative cassette exon 5 of chicken troponin T
(cTNT E5) whose exclusion determines the expression of
the dsRed protein whereas its inclusion causes expression
of GFP, with both fluorescent proteins being directed to
the nucleus. This reporter is useful to study AS regulation
changes in steady-state. However, since the response to UV-
induced DNA damage is transient and UV treatment in-
duces a strong shut-down of transcription and translation,
some major changes were mandatory. First, we subcloned
the reporter under the control of the inducible Tet-on pro-
moter of the pcDNA5/FRT/TO plasmid that, additionally,
allows direct integration into the genome of the transfected
cells via the Flp-In T-Rex system (Invitrogen). Second, since
the maturation half-time of dsRed is approximately 10 times
longer than that of GFP (28), we introduced three mu-
tations leading to amino acid changes (H41T, N42Q and
V44A) reported to promote faster maturation (29). The fi-
nal version of the construct with the fast maturating dsRed
(dsRed*) is depicted in Figure 1A. We obtained HeLa cells
stably transfected with this construct (HeLa eRGi cells).
Supplementary Figure S1 shows that dsRed* and GFP flu-
orescence increase comparably after induction by tetracy-
cline in HeLa cells stably transfected with the modified re-
porter, while cells transfected with an inducible version of
the original reporter only display GFP fluorescence 22 h af-
ter induction, suggesting that the modified reporter would
be more sensitive to detect changes in inclusion of the alter-
native exon upon external signals.
The next step was to validate the designed reporter to
evaluate the AS response to UV-induced DNA damage. In-
deed, UV irradiation of HeLa eRGi cells upregulates inclu-
sion of the cTNT exon E5 both at the mRNA (Figure 1B)
and protein (Figure 1C) levels. Importantly, flow cytome-
try analysis shows that the GFP/dsRed* fluorescence ratio
increases proportionally to the UV dose in a linear fash-
ion (Figure 1D). Images obtained by epifluorescence mi-
croscopy (Figure 1E) also confirm that dsRed* fluorescence
decreases with UV irradiation compared to GFP signal.
As an important control to demonstrate that the ob-
served changes in fluorescence ratios are not due to artifac-
tual features of the fluorescent proteins of the reporter, we
obtained HeLa cells stably transfected with a ‘reverse’ re-
porter in which exon inclusion causes dsRed* fluorescence
while exclusion promotes GFP signal (Supplementary Fig-
ure S2A). Both mRNA analysis and flow cytometry (Sup-
plementary Figure S2B) clearly show that the effects of UV
irradiation are reproduced with the ‘reverse’ reporter.
A second important aspect to investigate is if the upreg-
ulation of cTNT E5 inclusion follows the kinetic coupling
mechanism. We have previously shown that DNA lesions
caused by UV trigger RNAPII hyperphosphorylation lead-
ing to slow transcriptional elongation rates which in turn
affect AS decisions (15,20). Figure 1F shows that the in-
crease in inclusion of cTNT E5 caused by UV is abolished
when transcription is carried out by an RNAPII with a
non-phosphorylatable CTD at serines 2 and 5 (15) (lanes
1–4). In turn, transcription by a slow mutant (hC4 mutant,
R749H) of RNAPII increases cTNT E5 inclusion (lane 5),
coherently with a kinetic regulation of the AS of this exon
(3). Furthermore, removal of the cyclobutane pyrimidine
dimers (CPDs), the most abundant DNA lesions caused by
UV, by ectopic expression of a marsupial CPD-specific pho-
tolyase in HeLa cells (20) also reduces the UV effect on
cTNT E5 inclusion (Figure 1G). Altogether, results in Fig-
ure 1, Supplementary Figures S1 and S2 support the use
of the HeLa cell line stably transfected with the improved
fluorescent reporter to identify new protein kinases partici-
pating in the UV effect on AS, based on its kinetic coupling
with transcription.
GSK-3 inhibitors specifically reduce the UV effect on alter-
native splicing
To perform a screening of protein kinase inhibitors, HeLa
cells stably transfected with the improved fluorescent re-
porter were plated in 96-well plates at ∼10 000 cells per well.
Twenty-four hours later, the cells were exposed or not to UV
irradiation at a dose of 5 J/m2 and treated with 688 different
ATP-competitive protein kinase inhibitors, present in the
GlaxoSmithKline published kinase inhibitor set 2 (PKIS2)
library, at a final concentration of 0.1 M. The expression
of the reporter was induced by addition of tetracycline and,
24 h later, cells were harvested by trypsinization and flu-
orescence was assessed in a robot-assisted flow cytometer
(Supplementary Figure S3A). Supplementary Figure S3B
shows a diagram of the screening analysis and data treat-
ment. Screening results are shown in Supplementary Ta-
ble S1. Surprisingly, only 8 inhibitors reduced the effect of
UV light on cTNT E5 inclusion by at least 15% and five
of these were reported to target glycogen synthase kinase
3 (GSK-3, Figure 2A). In order to validate the effects of
GSK-3 inhibition we tested two of the inhibitors from the
library (GW806290X and GW805758X) and two commer-
cial GSK-3 inhibitors (CHIR90221 and AR-A 014418, Fig-
ure 2B) in the AS response to UV exposure (Figure 2C-E).
Unlike GW806290X and GW805758X, the commercial in-
hibitors CHIR and AR-A are selective for GSK-3 and do
not inhibit Cdks (30,31). Commercial inhibitor activity was
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1 2 3 4 5Lane: 1 2 3 4Lane:
Figure 1. An alternative splicing fluorescent reporter system to study the transcriptional response to UV-induced DNA damage. (A) Diagram of the
enhanced alternative splicing fluorescent reporter used to stably transfect HeLa cells by the Flp-In techonology (HeLa eRGi cells). Inclusion of the 28 nt
alternative exon (cTNT E5) results in an mRNA that is translated to GFP, while the mRNA resulting from its skipping is translated to dsRed*. (B) HeLa
eRGi cells were UV irradiated (or not) with 15 J/m2 and tetracycline was immediately added to induce the transcription of the reporter. Three hours after
irradiation, total RNA was prepared and AS patterns of the alternative splicing fluorescent minigene were assessed by radioactive RT-PCR with specific
primers. The ratio inclusion/skipping is shown. (C) Western blot of the reporter-encoded proteins was performed with an anti-Flag antibody. HeLa eRGi
cells were treated as in (B) and harvested in Laemmli buffer 24 hours after irradiation. (D) Flow cytometry of HeLa eRGi cells treated as in (B), with
different doses of UV light, 24 h after irradiation. The left panel is a histogram of GFP/dsRed* fluorescence signal at each UV dose. The right panel shows
the quantification of the mean GFP/dsRed* signal of 3 independent experiments. The r2 of the linear regression is shown. (E) Epifluorescence microscopy
representative fields of HeLa eRGi cells treated as in (B), 24 hours after irradiation. The figure shows GFP signal, dsRed* signal and their merge. (F) HeLa
eRGi cells were transfected with WT, A2A5 and C4 -amanitin resistant Rpb1 expression constructs. Twenty-four hours after transfection, -amanitin was
added at 100 g/ml to induce the degradation of the endogenous Rpb1. Twenty-four hours later, cells were treated as in (B). Three hours after irradiation,
total RNA was prepared and AS patterns were assessed by radioactive RT-PCR. (G) HeLa cells stably expressing the marsupial CPD photolyase were
transfected with the alternative splicing fluorescent reporter construct shown in (A). Cells were treated as in (B) followed by 2 h under white light (or not as
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Figure 2. Screening of protein kinase inhibitors unveils GSK-3 as a kinase involved in the transcriptional response to UV-induced DNA damage (A)
Hits resulting from the screening of the PKIS2 library with the alternative splicing fluorescent reporter. (B) Structure of the commercial selective GSK-3
inhibitors used. (C–E) HeLa cells were UV irradiated (or not) with 15 J/m2 and the inhibitors GW8057578X, GW806290, CHIR, AR-A or DMSO as
vehicle control were added immediately. Three hours after irradiation, total RNA was prepared and AS patterns of the alternative exons E2 of TMEM188
(C), E9a of EED (D) and E2a of TBX3 (E) were assessed by radioactive RT-PCR with specific primers.
at Ser33, Ser37 and Thr41, and of Tau at Ser396 (Supple-
mentary Figure S3C), two well-known GSK-3 substrates
(23). Inclusion of TMEM188 E2 is promoted by UV irradi-
ation (Figure 2C, lanes 1 and 2) and this effect is abolished
(lanes 3–6, 9 and 10) or reduced (lanes 7 and 8) by GSK-3
inhibitors. In the case of EED E9, where UV light also in-
creases exon inclusion (Figure 2D, lanes 1 and 2), the four
inhibitors abolish the UV effect (lanes 3–10) but they dis-
play an effect per se in promoting EED E9 inclusion. Un-
like the two previous events, TBX3 E2a corresponds to an
event in which UV light and slow elongation promote exon
skipping (20). This downregulatory effect (Figure 2E, lanes
1 and 2) is also abolished by the four tested inhibitors (lanes
3–10), which display a per se effect similar to that of UV ir-
radiation. It is worth noting that GSK-3 inhibition per se
modifies AS patterns in non-irradiated cells. There are sev-
eral possible explanations for this. This effect can be cou-
pled to transcription if GSK-3 acts as an RNAPII kinase.
It can also be a consequence of changes in splicing factor
activities. This would not be surprising given that GSK-3
phosphorylates several splicing factors (32). Finally, it can
be due to changes in mRNA isoforms stability, and thus not
dependent on de novo transcription. The latter hypothesis
was overruled. As shown before (15), the UV effect on AS is
abolished by treatment of the cells with the transcription in-
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nomycin D, the GSK-3 inhibitor CHIR has no further ef-
fects per se or in the UV-treated cells on the three model AS
events assessed in Figure 2 (Supplementary Figure S4A–C).
GSK-3 is an RNAPII phospho-CTD kinase
The inhibition of the UV effect on AS by GSK-3 inhibitors
suggests that GSK-3 may be involved directly or indi-
rectly in the phosphorylation of RNAPII. As a first ap-
proach we tested the effects of the four GSK-3 inhibitors
in RNAPII western blot (Figure 3A). Notably, whereas the
Cdk9 inhibitor DRB completely prevents RNAPII phos-
phorylation, both in irradiated and non-irradiated cells
(lanes 11–14), GSK-3 inhibition only prevents RNAPII
hyperphosphorylation caused by UV irradiation (lanes 1–
10). This suggests that GSK-3 might be acting on pre-
phosphorylated CTD (see below). Given that RNAPII is
phosphorylated when engaged in transcription, we pre-
pared differential cell extracts based on a salt extractabil-
ity protocol (21). This protocol allows to obtain a high salt
extract, which is enriched in transcribing RNAPII, and a
low salt extract. Supplementary Figure S4D shows that, al-
though RNAPII is present in both types of extract, UV-
induced RNAPII hyperphosphorylation is observed in the
high salt extract but not in the low salt extract (compare
lanes 1 and 2 versus lanes 5 and 6). However, if cells are
treated with the GSK-3 inhibitor CHIR, RNAPII hyper-
phosphorylation in response to UV is impaired (compare
lanes 2 and 4).
Figure 3A also reveals that UV irradiation induces an
observable decrease in total RNAPII western blot signal,
no matter what inhibitor is used. This decrease is caused
by proteasome-mediated RNAPII degradation (33). This
opens the possibility that the effects of the GSK-3 inhibitors
themselves were due to differential promotion or inhibi-
tion of the degradation of specific RNAPII isoforms. Fig-
ure 3B shows that pre-treatment with the proteasome in-
hibitor MG132 abolishes the observed degradation by UV
and, most importantly, does not affect the abrogation of the
UV effect by GSK-3 inhibition.
Given that the CTD repeats match the GSK-3 target con-
sensus site (Figure 3C), we performed in vitro phosphoryla-
tion assays of recombinant CTD expressed in bacteria by
the Cdk9 and/or GSK-3 endogenous kinases, immunop-
urified from HEK293T cells. Figure 3D shows that Cdk9
is able to phosphorylate the recombinant CTD with prefer-
ence towards Ser5 over Ser2 (lane 3), as previously reported
(34). In fact, if Cdk9 is incubated with the CTD for shorter
times, no P-Ser2 signal is detected (lane 4). Figure 3E shows
that immunopurified GSK-3 can phosphorylate the CTD
at Ser2 to some extent (lane 3). However, when recombi-
nant CTD is pre-phosphorylated by Cdk9 (P-CTD), GSK-
3 phosphorylation efficiency increases by at least 5-fold
(compare lanes 3 and 5). Moreover, GSK-3 is also able
to phosphorylate Ser5 of a CTD pre-phosphorylated by
Cdk9 (Supplementary Figure S5A). To rule out that the im-
munopurified preparation of GSK-3 contained contami-
nating kinases other than GSK-3 that could be responsi-
ble for the phosphorylation of phospho-CTD, we expressed
HA-tagged WT GSK-3 and the kinase-dead (KD) mutant
K85A (35) in HEK293T cells and immunopurified them
with an anti-HA antibody. Unlike WT HA-GSK-3, the
KD mutant is not able to phosphorylate the recombinant
CTD pre-phosphorylated by Cdk9 neither at Ser2 (Figure
3F) nor at Ser5 (Supplementary Figure S5B). These exper-
iments reveal that, consistently with the requirements to
phosphorylate its canonical substrates like -catenin and
Tau (23), GSK-3 efficiently acts as a CTD kinase when the
CTD is already phosphorylated. In summary, our results
suggest that GSK-3 phosphorylates phospho-CTD in a di-
rect manner.
Redundancy and requirement of GSK-3 and GSK-3
The two paralogue genes GSK-3 and GSK-3 share an
85% of amino acid sequence identity that increases to >95%
at the catalytic domain. Although the two forms differ
by the presence of an extra glycine-rich segment in GSK-
3, there is evidence that they might be redundant in the
phosphorylation of certain targets (36). To investigate this
possibility, we obtained CRISPR/Cas 9 knockouts of ei-
ther GSK-3 or  in HeLa cells (Supplementary Figure
S5C). After several attempts, we failed to obtain the double
knockout in these cells which suggests that the complete ab-
sence of GSK-3 activity is not compatible with HeLa cell vi-
ability. The apparent essentiality of GSK-3 is not surprising,
considering that ESCs differentiation is impaired in GSK-
3 double KO cells (36). In any case, individual ablation of
GSK-3 or GSK-3 did not prevent the UV effect on AS
(Supplementary Figure S5D) nor on RNAPII hyperphos-
phorylation (Supplementary Figure S5E), indicating that
the two GSK-3 forms play similar roles in the mechanism
studied here and are therefore redundant. However, when
GSK-3 was silenced using siRNA in the GSK-3 knock-
out cells, we were able to detect up to a 40% reduction in
RNAPII hyperphosphorylation in response to UV irradi-
ation. Conscious that still this evidence is not sufficiently
strong, we explored another approach to validate the results
with pharmacological inhibitors.
Overexpression of a kinase-dead dominant negative GSK-3
mutant reduces the UV effect on alternative splicing
In search for stronger genetic evidence to independently val-
idate the results observed with the GSK-3 inhibitors we
overexpressed the kinase-dead (KD) K85A GSK-3 mu-
tant described above (Figure 3B). This mutant version of
GSK-3 competes with endogenous active GSK-3 when ex-
pressed in cells, and thus acts in a dominant negative man-
ner (37). Limitations of this approach due to low transfec-
tion efficiency were overcome by co-transfecting the GSK-
3 expression plasmids with inducible AS reporter mini-
genes that contain intronic and exonic elements of an en-
dogenous AS event under the control of a tetracycline in-
ducible promoter. Furthermore, in order to avoid competi-
tion between endogenous GSK-3 and the GSK-3 overex-
pressed, these experiments were performed in GSK-3 null
HeLa cells. As these cells derive from the HeLa Flp-In T-
REx cells, they stably express the tetracycline repressor.
In brief, GSK-3 null cells were co-transfected with HA-
tagged K85A GSK-3 mutant (or GSK-3 WT as a con-
trol) together with a TBX3 exon E2a AS reporter mini-
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Figure 3. GSK-3 is an RNAPII phospho-CTD kinase and its activity is necessary for RNAPII hyperphosphorylation and AS response after UV-induced
DNA damage (A) HeLa cells were UV irradiated (or not) with 15 J/m2 and the inhibitors GW8057578X, GW806290, CHIR, AR-A or DMSO as vehicle
control were added immediately. For DRB treatment, cells were pretreated for 2 h with DRB before UV irradiation. Two hours after irradiation, cells were
harvested in Laemmli buffer and RNAPII phosphorylation patterns were assessed by western blot of total Rpb1. (B) HeLa cells were pre-treated (or not)
with the proteasome inhibitor MG132 for 1 hour prior to irradiation. Subsequent treatment and sample analysis were performed as in (A). (C) Diagram
of GSK-3 consensus site and putative GSK-3 target sites in a diheptad of the RNAPII CTD depending on which residue is previously phosphorylated.
(D) Recombinant GST-CTD purified from bacteria was incubated with Cdk9 immunopurified from HEK293T cells in the presence of ATP. Cdk9 with
no substrate and GST-CTD with no kinase were incubated in the presence of ATP as a control. After thirty minutes (or one hour), kinase assays were
stopped by addition of Laemmli buffer and samples were analyzed by western blot with antibodies raised against CTD P-Ser2, CTD P-Ser5, GST and
Cdk9. (E) GSK-3 was immunopurified from HEK293T cells. The kinase was incubated in the presence of ATP with GST-CTD purified from bacteria or
with GST-CTD pre-phosphorylated (P-CTD) by Cdk9 as in (C). GSK-3 with no substrate was incubated in the presence of ATP as a control. Additionally,
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AS reporter minigene (TMEM188-E2 minigene). Twenty-
four hours after transfection, cells were irradiated or not
with 15 J/m2 of UV light and tetracycline was immediately
added to induce the AS reporter expression. Three hours
later, cells were harvested for total RNA purification and
analysis of minigene AS patterns were performed by ra-
dioactive RT-PCR with specific primers. Figure 3G (lanes
1 and 2) shows that UV irradiation causes an increase in
TMEM188-E2 minigene exon E2 inclusion when cells over-
express GSK-3 WT, consistent with what happens with
the endogenous TMEM188 exon E2 event (Figure 2C, lanes
1 and 2). However, upon overexpression of the KD domi-
nant negative mutant (Figure 3G, lanes 3 and 4), there is no
UV-effect on TMEM188-E2 minigene AS. Similarly, UV-
irradiation increases TBX3-E2a minigene exon E2a skip-
ping in cells overexpressing GSK-3 WT (Figure 3H, lanes
1 and 2) while overexpression of the KD dominant nega-
tive GSK-3 leads to an important reduction in UV-elicited
exon E2a skipping (Figure 3H, lanes 3 and 4). In summary,
these results reveal that the effect of GSK-3 pharmacolog-
ical inhibitors on AS regulation in response to UV irradi-
ation is reproduced if GSK-3 activity is inhibited competi-
tively by the overexpression of a KD dominant negative mu-
tant of GSK-3.
RNAPII densities and histone 3′end processing are affected
by GSK-3 inhibition
It is now accepted that UV irradiation causes a global re-
duction not only in RNAPII transcription initiation but
also in elongation rates and that this effect is in trans and
independent of the impairments to RNAPII progression
caused in cis by the actual DNA lesions (15,16,20). Conse-
quently, RNAPII ChIP experiments should reveal a relative
decrease in promoter signal and an increase in intragenic
signal upon UV treatment. We therefore decided to test if
GSK3 inhibition affected RNAPII densities on the model
gene TBX3 by total RNAPII ChIP (Figure 4A). In fact, UV
irradiation causes an important increase in RNAPII densi-
ties along the whole TBX3 gene, except at its promoter re-
gion where the ChIP signal decreases. Such accumulation of
RNAPII in the gene body is abolished when UV irradiated
cells are treated with the GSK-3 inhibitor CHIR.
The Bentley lab has recently shown that inhibition
of transcription elongation either by a slow mutant of
RNAPII or by UV irradiation causes a change in 3′ end pro-
cessing of the mRNAs encoding replicative histones (38). In
normal conditions, the 3′ end of these mRNAs consists in
a particular stem-loop structure. Slow elongation disrupts
the formation of the stem–loop structure, which switches 3′
end formation to cleavage and polyadenylation occurring
farther downstream. Therefore, slow elongation increases
the ratio between the long histone mRNAs, resulting from
cleavage and polyadenylation, over the short forms, result-
ing from stem–loop cleavage. This ratio could be used as
a proxy to evaluate RNAPII elongation. Accordingly, we
confirmed that UV irradiation increases the formation of
the long mRNA for both histones H3B and H2AG and,
most importantly, that these effects are greatly reduced by
removal of the UV photolesions with the CPD photolyase
approach used in Figure 1G (Figure 4B). As expected from
the roles found here for GSK3 on AS and RNAPII phos-
phorylation, CHIR and AR-A inhibit the UV effect on
promoting the longer mRNA isoforms of histones H3B
and H2AG (Figure 4C). Summarizing, results in Figure 4
suggest that GSK3 inhibition counteracts the inhibition of
RNAPII elongation triggered by UV-mediated DNA dam-
age.
GSK3 inhibition reverts pro-apoptotic effects of UV irradia-
tion
In an attempt to assess the biological implications of the
role of GSK-3 in the UV-induced DNA damage response,
we quantified the proportions of live, early apoptotic, late
apoptotic and necrotic cells by flow cytometry using pro-
pidium iodide and FITC-annexin V. Upon UV irradiation,
more than 95% of the cells are early or late apoptotic (com-
pare Figure 5A and B). While CHIR has no effect on apop-
tosis per se (Figure 5C), it downregulates the UV effect on
apoptosis by increasing the number of live cells from 3.8%
to 51% and concomitantly reducing the proportion of early
and late apoptotic cells to 45% (Figure 5D).
DISCUSSION
Our group has initially shown that UV treatment triggers a
transcriptional and AS response that includes RNAPII hy-
perphosphorylation, a decrease in RNAPII elongation rates
and genome-wide changes in AS patterns (15). Later, we
found that the repair of CPD DNA lesions by the global
genome nucleotide excision repair (GG-NER) machinery
triggered a signaling cascade ending in RNAPII phospho-
rylation, mediated by the DNA damage kinase ATR (20).
Development of a fluorescent AS reporter system
In this work, our focus was to identify novel kinases in-
volved in transcription and AS responses. To achieve this
goal, we developed a screening strategy based on the AS
fluorescent reporter originally designed by the Cooper lab
(27). The original construction is useful to study stimuli that
affect AS in the steady-state, but not for transient responses
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
samples were analyzed by western blot with antibodies raised against CTD P-Ser2, GST and GSK-3. The diagram below depicts the experiment outcome.
(F) HA-tagged WT or kinase dead (KD) GSK-3 were transfected in HEK293T cells and immunopurified with anti HA antibody. GST-CTD purified
from bacteria or P-CTD were incubated with WT GSK-3 or KD GSK-3 in the presence of ATP. After one hour, kinase assays were stopped by addition
of Laemmli buffer and samples were analyzed by western blot with antibodies raised against CTD P-Ser2, GST and HA. (G) HeLa GSK-3 null cells were
co-transfected with WT GSK-3 (GSK-3 WT) or the kinase-dead dominant negative K85A GSK-3 mutant (GSK-3 KD) and a TMEM188 exon E2
AS reporter minigene. Cells were UV irradiated (or not) with 15 J/m2 and tetracycline was added immediately to induce the AS reporter. Three hours after
irradiation, total RNA was prepared and AS patterns of the minigene were assessed by radioactive RT-PCR with specific primers. (H) HeLa GSK-3 null
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Figure 4. GSK-3 inhibition prevents the UV-induced reduction in RNAPII elongation rates (A) HeLa cells were UV irradiated (or not) with 15 J/m2 and
the inhibitor CHIR or DMSO as vehicle control were added immediately. Two hours later, cells were harvested for RNAPII ChIP. RNAPII density was
measured along the TBX3 model gene with the amplicons shown in the diagram. (B) HeLa cells stably transfected with the marsupial CPDs photolyase
were UV irradiated (or not) and incubated 2 h exposed to white light (or not) to activate the CPD photolyases. Three hours after irradiation, total RNA
was prepared and the quantity of long and total mRNA isoforms of histones H3B and H2AG were determined by RT-qPCR. The ratio long/total isoform
is shown. (C) Quantification of histone H3B and histone H2AG long/total mRNA isoforms in response to UV-induced DNA damage in cells treated or
not with the inhibitors CHIR and AR-A, three hours after irradiation.
like the one studied here. Therefore, we subcloned the re-
porter under a Tet-on promoter in a plasmid that allowed
us to obtain a HeLa stable cell line via the Flp-In T-Rex
system. Additionally, we introduced three point mutations
in the dsRed coding sequence in order to obtain a fast ma-
turing dsRed version (dsRed*), with a maturation half-time
comparable to that of GFP. This enhanced reporter proved
to be a useful tool to study UV induced changes in tran-
scription and AS (Figure 1).
Screening reveals GSK-3 as a central kinase in the transcrip-
tional and AS response to DNA damage
The optimized reporter was then used to screen the Glax-
oSmithKline published kinase inhibitor set 2 (PKIS2) li-
brary, composed of nearly 700 different ATP-competitive
protein kinase inhibitors. From the eight compounds that
reduced the AS response to UV treatment, five had GSK-
3 as a common target (Figure 2A). Therefore, we centered
our attention on understanding the role of this kinase in
the transcriptional and AS response to UV-induced DNA
damage. The role of GSK-3 was further validated with the
highly selective GSK-3 inhibitors CHIR99021 and AR-A
014418 (Figure 2B). It is important to note that, regarding
the inherent pleiotropic nature of ATP-competitive kinase
inhibitors, the use of different inhibitors is necessary to con-
firm the identity of the intervening kinase. In this sense, in
vitro kinase assay screenings with CHIR99021 and AR-A
014418 showed that while both drugs inhibit efficiently the
paralogues GSK-3 and GSK-3, their off-target kinases
are different (39).
GSK-3 phosphorylates the RNAPII CTD and affects elon-
gation rates and AS patterns in response to DNA damage
We observed that GSK-3 inhibition prevents the transcrip-
tional and AS response to UV-induced DNA damage at ev-
ery level. First, GSK-3 inhibition prevents changes in AS
patterns (Figure 2C–E), and this was also observed when,






/nar/advance-article-abstract/doi/10.1093/nar/gkaa322/5831188 by  ark@
fbm
c.fcen.uba.ar on 06 M
ay 2020
Nucleic Acids Research, 2020 11
Propidium iodide and FITC-annexin V staining





















































































Figure 5. GSK-3 inhibition prevents UV-induced apoptosis (A–D) HeLa
cells were UV irradiated with 30 J/m2 to induce apoptosis, and immedi-
ately treated (or not) with CHIR. Twenty-four hours after UV irradiation,
cells were stained with propidium iodide and FITC-annexin V to identify
live, early apoptotic, late apoptotic and necrotic cells.
overexpressed a kinase-dead dominant negative mutant of
GSK-3 (Figure 3G–H). It is fair to point out that, in some
cases, GSK-3 inhibition modifies AS patterns per se. This
is highly coherent with the role assigned here for GSK-3 as
an RNAPII CTD kinase, and in fact, genome-wide analyses
reveal that GSK-3 inhibition changes AS patterns globally
(40). In this sense, there is a possibility for GSK-3 to have
a role in transcription elongation in non-irradiated condi-
tions and thus its inhibition would induce changes in AS
regulation. Additionally, the change in AS patterns upon
treatment with GSK-3 inhibitors could be a consequence
of changes in splicing factor activities, since many of them
are phosphorylated by GSK-3 (32). Though this hypothesis
is plausible, its testing is beyond the scope of this work. Sec-
ond, while Cdk9 inhibition prevents general RNAPII phos-
phorylation, GSK-3 inhibition seems to prevent only UV-
induced RNAPII hyperphosphorylation. The relevance of
GSK-3 in this specific situation may be the reason why, up
to now, this activity has been out of sight (Figure 3A). Con-
sidering that the CTD sequence matches the GSK-3 target
consensus site (41), we speculated that RNAPII could be
a direct substrate of GSK-3 (Figure 3C). To test this hy-
pothesis, we purified a GST-CTD fusion protein expressed
in bacteria and immunopurified GSK-3 from HEK293T
cells. When incubated together in in vitro phosphorylation
conditions, GSK-3 phosphorylated the CTD mildly. How-
ever, if the CTD was subjected to a first round of phospho-
rylation by Cdk9, then GSK-3 was able to phosphorylate
efficiently this pre-phosphorylated CTD (Figure 3D-F and
Supplementary Figure S5A–B) both at Ser2 and Ser5. This
is not surprising, considering that GSK-3 requires a priming
phosphate around four residues C-terminal from the GSK-
3 target amino acid to properly accommodate the substrate
in its active site. In fact, GSK-3 yeast homologue Rim11
was shown to phosphorylate the CTD in Thr4 in vitro, but
its biological relevance was not assessed (14). Third and last,
GSK-3 inhibition prevents changes in elongation rates in re-
sponse to DNA damage. This was shown with two different
strategies: RNAPII densities were measured by ChIP exper-
iments in cells treated or not with UV light, and treated or
not with CHIR. UV treatment induces a relative decrease
in RNAPII ChIP signal in the promoter and an increase
in the gene body of the model gene TBX3. In turn, GSK-3
inhibition prevents the increase of the intragenic ChIP sig-
nal in response to UV treatment (Figure 4A). Alternatively,
we measured histone mRNA polyadenylation as a proxy to
evaluate RNAPII elongation rates: slow elongation induces
a switch from the short stem-loop cleaved isoforms towards
the long polyadenylated isoforms. This happens when cells
are treated with UV light, but in combination with CHIR
this switch is highly prevented (Figure 4C). Moreover, ge-
netic evidence suggests that both paralogues GSK-3 and
GSK-3 are redundant in this pathway (Supplementary
Figure S5C-E). Altogether, our results suggest an impor-
tant and direct role for GSK-3 in the UV-induced RNAPII
hyperphosphorylation and the consequent changes in gene
expression and AS patterns. However, the priming kinase(s)
that phosphorylate(s) RNAPII prior to GSK-3 remain(s)
unidentified. While Cdk9 is an obvious candidate (21,22),
we cannot rule out if other kinase(s) may be involved.
Inhibition of RNAPII hyperphosphorylation versus degrada-
tion
We show here that, unlike DRB, GSK-3 inhibitors do not
inhibit basal RNAPII phosphorylation but do inhibit UV-
triggered CTD hyperphosphorylation (Figure 3A). Fur-
thermore, both the UV-triggered hyperphosphorylation
and its abrogation by GSK-3 inhibition are also observed
when the proteasome activity is inhibited by MG132. This
evidence is highly consistent with the in trans mechanism
whose initial step is recognition of the DNA lesions by the
GG-NER complexes and does not involve recognition of
the lesion by RNAPII itself, followed by ubiquitylation and
subsequent proteasomal degradation, as is characteristic of
TC-NER.
GSK-3 collaborates in UV-induced apoptosis
There is compelling evidence that supports a role for GSK-
3 in apoptosis. Intriguingly, while in the extrinsic apopto-
sis pathway GSK-3 acts as an anti-apoptotic factor, in the
intrinsic pathway GSK-3 promotes apoptosis (42,43). UV-
induced DNA damage triggers the intrinsic apoptosis path-
way, that includes changes in gene expression profiles and
is characterized by the release of cytochrome c from mito-
chondria that together with APAF-1 and procaspase-9 form
the apoptosome. Apoptotic cells undergo a massive desta-
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was reported to promote apoptosis by phosphorylating key
transcription factors, proteins that contribute to mitochon-
dria disruption and proteins that destabilize the cytoskele-
ton, among others. These roles of GSK-3 were shown upon
cell treatment with UV, camptothecin and etoposide (44–
47). In Figure 5, we show that, as reported, GSK-3 inhibi-
tion prevents UV-induced apoptosis. However, the novelty
of the present work resides on GSK-3 regulating gene ex-
pression profiles, including AS patterns, by directly modify-
ing RNAPII elongation rates. The central role of GSK-3 in
cell functioning is supported by evidence that its misregula-
tion has been implicated in multiple pathologies including
diabetes, cancer, bipolar disorder, cardiac disease and neu-
rodegenerative conditions such as Alzheimer and Parkin-
son (48,49). Our demonstration that GSK-3 is an RNAPII
phospho-CTD kinase and that its activity contributes to
the modulation of RNAPII elongation opens the way to in-
vestigate if these mechanisms are implicated in the above-
mentioned pathologies.
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5. Batsché,E., Yaniv,M. and Muchardt,C. (2006) The human SWI/SNF
subunit Brm is a regulator of alternative splicing. Nat. Struct. Mol.
Biol., 13, 22–29.
6. Nojima,T., Gomes,T., Grosso,A.R.F., Kimura,H., Dye,M.J., Dhir,S.,
Carmo-Fonseca,M. and Proudfoot,N.J. (2015) Mammalian NET-Seq
reveals genome-wide nascent transcription coupled to RNA
processing. Cell, 161, 526–540.
7. Bartkowiak,B., Liu,P., Phatnani,H.P., Fuda,N.J., Cooper,J.J.,
Price,D.H., Adelman,K., Lis,J.T. and Greenleaf,A.L. (2010) CDK12
is a transcription elongation-associated CTD kinase, the metazoan
ortholog of yeast Ctk1. Genes Dev., 24, 2303–2316.
8. Liang,K., Gao,X., Gilmore,J.M., Florens,L., Washburn,M.P.,
Smith,E. and Shilatifard,A. (2015) Characterization of human
cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in
C-Terminal domain phosphorylation, gene transcription, and RNA
processing. Mol. Cell. Biol., 35, 928–938.
9. Hintermair,C., Heidemann,M., Koch,F., Descostes,N., Gut,M.,
Gut,I., Fenouil,R., Ferrier,P., Flatley,A., Kremmer,E. et al. (2012)
Threonine-4 of mammalian RNA polymerase II CTD is targeted by
Polo-like kinase 3 and required for transcriptional elongation. EMBO
J., 31, 2784–2797.
10. Di Vona,C., Bezdan,D., Islam,A.B., Salichs,E., López-Bigas,N.,
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49. Tejeda-Muñoz,N. and Robles-Flores,M. (2015) Glycogen synthase







/nar/advance-article-abstract/doi/10.1093/nar/gkaa322/5831188 by  ark@
fbm
c.fcen.uba.ar on 06 M
ay 2020
